In conclusion, upcyte® hepatocyte cultures are characterized by a differentiated phenotype and exhibit functional phase I, phase II and transporter activities. These data support the use of upcyte® hepatocytes for various applications, such as as metabolism & toxicity screening assays, viral infection and 3D culture. Moreover, this technology allows for the generation of large batches of upcyte® hepatocytes (up to 12 x 10 9 cells per donor), enabling a reproducible and standardized experimental setting.
INTRODUCTION
Isolated liver cells, such as hepatocytes, liver sinusoidal endothelial cells (LSECs), Kupffer Cells and hepatic stellate cells, are frequently used to study hepatic metabolism, toxicity and disease pathogenesis. However, the current in vitro models exhibit several disadvantages, e.g. short culture longevity and artificial culture conditions focusing on a single cell type in 2D culture. The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (hepatocytes and LSECs) and/or the change from a quiescent to an activated state (hepatic stellate cells). To overcome this, we have developed a technique which causes primary human hepatocytes to proliferate up to 40 population doublings whilst retaining an adult and metabolically competent phenotype with phase I (Cytochrome P450) and phase II activities when cultured at confluence. The resulting cells are called "upcyte® hepatocytes" and combine proliferation with drug metabolizing activity, a feature which makes them uniquely applicable to metabolism and toxicity studies. Good correlation between predicted CL H and observed in vivo CL values was observed for the subset of low CL drugs (shown here). CL H for 73% (8 of 11 compounds) were predicted within twofold of in vivo CL nonrenal and within threefold for 82% (9 of 11 compounds) with a trend for overpredicting the actual in vivo rate.
Data represent mean 6±S.D. of triplicate incubations per compound (n = 3) determined at day 7 in sandwich culture. Solid line represents conformity, and dashed lines two-and threefold error range. The set of reference drugs was subdivided into low and intermediatecleared compounds (shown here: low): alprazolam (1), prednisolone (2), diazepam (3), voriconazole (4), tolbutamide (5), meloxicam (6), warfarin (7), glimepiride (8), riluzole (10), oxazepam (11).
Tolosa et al., 
self-assembly in Matrigel TMcoated 24-well plates
After 72h, cells showed formation of structures resembling a liver blossom. Hepatocytes were located in the center and formed the outer petals (HIF-1α). LSECs formed an inner ring (CD31), whereas HSCs revealed a typical, "star-shaped" morphology (α-SMC).
Fenech et al., 2010 upcyte® hepatocytes can discriminate compounds of 3 classes
The requirements for the MN assay are proliferating and metabolically competent cells. While pHH lack proliferation, cells lines lack expression of metabolizing enzymes. The use of S9 extract as exogenous metabolizing system involves a high "false positive" rate. Incubation for 96 h (long term treatment for 2 population doublings) allowed upcyte® cells to discriminate correctly between true positives (direct and bio-activated), true negatives and false positives.
NS5A DAPI upcyte® hepatocytes support HCVcc infection
HCV infects hepatocytes in vivo, but infectivity of primary human hepatocytes in vitro is minimal. To assess whether our upcyte® hepatocytes support the full lifecycle of the HCV cell culture variant HCVcc, we exposed differentiated hepatocytes (donors 740 and 653-03) to culture medium containing infectious particles of the JC1 genotype expressing an NS5A-RFP fusion protein.
Hepatocytes from both donors showed strong NS5A staining. More than 80% of the cells were infected in both cultures. NS5A-RFP levels significantly increased over time, reaching a 20-26-fold induction at day 9 post infection. Production of infectious particles showed a similar trend, stabilizing after day 9 and reaching 8,000 focus-forming unit (FFU) per milliliter for donor 653-03.
upcyte® hepatocytes have similar phase II activities compared to primary hepatocytes
Major hepatic phase II enzymes in humans are UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT) and glutathione S-transferase (GST). Phase II enzyme activities in upcyte® hepatocytes generated from different donors were similar to those of freshly isolated primary human hepatocytes (data not shown).
acute and repeated-dose toxicity using sub-cytotoxic concentrations
Exposure time length had dramatic effects on the toxicity profile of a compound. For APAP, no effect was observed after 24 h, whereas 1-week treatment significantly induced apoptosis, mitochondrial depolarization, ROS production and intracellular Ca 2+ levels. Other tested compounds caused some effects after 24 h, although a significant difference was detected between the two incubation periods at the lowest concentration. CIT (non hepatotoxic control) did not produce any significant effects after 24 h or 1 week treatment. 
